In a January 2024 study published in Medicine & Science in Sports & Exercise, researchers have uncovered significant drug use among ultrarunners. The study, led by Dr. Paul Robach and his team, used an innovative urine sampling method to accurately measure the prevalence of drug use in these endurance athletes and compared it with reported drug use through a questionnaire.
Novel Method Unveils True Drug Use
Traditional methods for assessing drug use in athletes, such as doping controls and questionnaires, have often faced challenges regarding accuracy and honesty in responses. To address this, the research team implemented a new approach by collecting urine samples from male participants using blind, automated urinals at the start of ultramarathon races. This method provided a more accurate measure of drug use compared to self-reported data.
Key Findings
The study involved analyzing 412 urine samples and comparing the results with responses from 2931 male and female runners who completed an anonymized, randomized-response questionnaire regarding their drug use.
The findings were interesting:
- 49.8% of urine samples contained at least one substance.
- 16.3% of samples contained one or more prohibited substances.
The most common substances detected included:
- Nonsteroidal anti-inflammatory drugs (NSAIDs): 22.1%
- Acetaminophen: 15.5%
- Opioids: 6.6%
- Diuretics: 4.9%
- Hypnotics: 4.4%
- Glucocorticoids: 2.7%
- Beta-2 agonists: 2.2%
- Cannabinoids: 1.9%
- Stimulants: 1.2%
Interestingly, no samples contained erythropoietin-receptor agonists (EPO) or suspicious levels of testosterone.
Questionnaire vs. Urine Sample Results
The questionnaire results showed lower reported usage rates:
- Acetaminophen: 13.6%
- NSAIDs: 12.9%
No prohibited substances were reported by participants.
This discrepancy highlights the reliability of the urine sampling method over self-reported data, revealing a higher actual prevalence of both legal and illegal substance use in ultrarunners.
Implications for Sports Medicine
The study concludes that while the use of NSAIDs and painkillers is prevalent among ultramarathon runners, the usage of performance-enhancing drugs remains relatively low.
The implementation of blind urine sampling methods can significantly enhance the accuracy of drug use assessments in competitive sports, providing valuable insights for sports medicine and anti-doping efforts.
Dr. Robach and his colleagues’ research highlights the need for continued development of reliable testing methods to ensure the integrity of competitive sports and the health and safety of athletes.
Interested in reading the full study? You can find it here.
